Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: A randomised controlled trial

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  Din, Jehangir N ^a   Sarma, Jaydeep ^b   Harding, Scott A ^c   Lyall, Karin ^a   Newby, David E ^a   Flapan, Andrew D ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c WELLINGTON HOSPITAL   (New Zealand)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CD40 LIGAND; FIBRIN; NITROPRUSSIDE SODIUM; OLIVE OIL; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; DIET SUPPLEMENTATION; FIBRINOLYSIS; FOREARM BLOOD FLOW; HEART INFARCTION; HUMAN; LIPID COMPOSITION; MALE; MONOCYTE; PHOSPHOLIPID BLOOD LEVEL; THROMBOCYTE ACTIVATION; TREATMENT DURATION; VASODILATATION; VITAMIN SUPPLEMENTATION;

EID: 84885335896     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003054     Document Type: Article

References (47)

1. Din JN, Newby DE, Flapan AD Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ 2004;328:30-5. (Pubitemid 38067742)
2. Burr ML, Fehily AM, Gilbert J.F., et al Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61. (Pubitemid 19234807)
3. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto miocardico. Lancet 1999;354:447-55.
4. Yokoyama M, Origasa H, Matsuzaki M., et al Japan EPA lipid intervention study (JELIS) Investigators. Lancet 2007;369:1090-8.
5. Marchioli R, Barzi F, Bomba E., et al Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903. (Pubitemid 34437615)
6. Leaf A, Kang JX, Xiao Y.F., et al Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003;107:2646-52. (Pubitemid 36667234)
7. Brouwer IA, Raitt MH, Dullemeijer C, et al Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009;30:820-6.
8. Bowker TJ, Wood DA, Davies M.J., et al Sudden, unexpected cardiac or unexplained death in England: a national survey. QJM 2003;96:269-79. (Pubitemid 36432386)
9. Oliver JJ, Webb DJ, Newby DE Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 2005;25:2470-9. (Pubitemid 43732266)
10. Fox KA, Robison AK, Knobb R.M., et al Prevention of coronary thrombosis with subthrombolytic doses of tissue type plasminogen activator. Circulation 1985;72:1346-54. (Pubitemid 16126815)
11. Jungi TW, Spycher MO, Nydegger U.E., et al Platelet-leucocyte interaction: selective binding of thrombin-stimulated platelets to human monocytes, polymorphonuclear leucocytes, and related cell lines. Blood 1986;67:629-36. (Pubitemid 16130249)
12. Schonbeck U, Lippy P. CD40 signaling and plaque instability. Circ Res 2001;89:1092-103. (Pubitemid 34627866)
13. Huo Y, Schober A, Forlow S.B., et al Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-7. (Pubitemid 36098261)
14. Zeiher AM, Drexler H, Wollschlager H., et al Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
15. Sarma J, Laan CA, Alam S, et al Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-71. (Pubitemid 34517160)
16. Tousoulis D, Antoniades C, Nikolopoulou A., et al Interaction between cytokines and sCD40 L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007;37:623-8. (Pubitemid 47063099)
17. Din JN, Archer RM, Harding S.A., et al Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers. Heart 2013;99:168-74.
18. Din JN, Harding SA, Valerio C.J., et al Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis 2008;197:290-6. (Pubitemid 351284475)
19. Newby DE, Wright RA, Ludlam C.A., et al An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997;78:1242-8. (Pubitemid 27464593)
20. Tagawa H, Shimokawa H, Tagawa T., et al Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilation in patients with coronary artery disease. J Cardiovasc Pharmacol 1999;33:633-40. (Pubitemid 29164828)
21. Mori TA, Watts GF, Burke V, et al Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000;102:1264-9.
22. Chin JP, Gust AP, Nestel P.J., et al Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993;21:22-8. (Pubitemid 23006448)
23. Goodfellow J, Bellamy MF, Ramsey M.W., et al Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000;35:265-70. (Pubitemid 30125512)
24. McVeigh GE, Brennan GM, Johnston G.D., et al Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin- dependent) diabetes mellitus. Diabetologia 1993;36:33-8. (Pubitemid 23018332)
25. Morgan DR, Dixon LJ, Hanratty C.G., et al Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure. Am J Cardiol 2006;97:547-51. (Pubitemid 43190048)
26. Woodman RJ, Mori TA, Burke V, et al Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003;166:85-93. (Pubitemid 35449604)
27. Wong CY, Yiu KH, Li S.W., et al Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med 2010;27:54-60.
28. Skulas-Ray A.C., Kris-Etherton PM, Harris W.S., et al Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011;93:243-52.
29. Tagawa T, Hirooka Y, Shimokawa H., et al Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertens Res 2002;25:823-9. (Pubitemid 36024636)
30. Haberka M, Mizia-Stec K, Mizia M., et al N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction. Clin Nutr 2011;30:79-85.
31. Kristensen SD, Iversen AM, Schmidt EB n-3 Polyunsaturated fatty acids and coronary thrombosis. Lipids 2001;36(Suppl):S79-82. (Pubitemid 34106213)
32. Smith P, Arnesen H, Opstad T., et al Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulants or matching placebo. Thromb Res 1989;53:467-74. (Pubitemid 19114480)
33. Mehta J, Lawson D, Saldeen TJ Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake. Am Heart J 1988;116(5 Pt 1):1201-6. (Pubitemid 18265638)
34. Spannagl M, Drummer C, Fröschl H, et al Plasmatic factors of haemostasis remain essentially unchanged except for PAI activity during n-3 fatty acid intake in type I diabetes mellitus. Blood Coagul Fibrinolysis 1991;2:259-65.
35. Finnegan YE, Howarth D, Minihane A.M., et al Plant and marine derived (n-3) polyunsaturated fatty acids do not affect blood coagulation and fibrinolytic factors in moderately hyperlipidemic humans. J Nutr 2003;133:2210-13. (Pubitemid 36841541)
36. Hellsten G, Boman K, Saarem K., et al Effects on fibrinolytic activity of corn oil and a fish oil preparation enriched with omega-3-polyunsaturated fatty acids in a long-term study. Curr Med Res Opin 1993;13:133-9. (Pubitemid 23256075)
37. Toft I, Bønaa KH, Ingebretsen OC, et al. Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol 1997;17:814-19. (Pubitemid 27209256)
38. Hrafnkelsdottir T, Gudnason T, Wall U., et al Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost 2004;2:1960-8. (Pubitemid 40192750)
39. Robinson SD, Ludlam CA, Boon N.A., et al Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2007;27:1651-6. (Pubitemid 46986123)
40. Treasure CB, Klein JL, Weintraub W.S., et al Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
41. Mancini GB, Henry GC, Macaya C, et al Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996;94:258-65. (Pubitemid 26266107)
42. Rauch B, Schiele R, Schneider S., et al OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-9.
43. Galan P, Kesse-Guyot E, Czernichow S., et al SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010;341:c6273.
44. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26.
45. Newby DE, Witherow FN, Wright R.A., et al Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo. Heart 2002;87:48-53. (Pubitemid 34074952)
46. Witherow FN, Dawson P, Ludlam C.A., et al E. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol 2002;40:961-6. (Pubitemid 34994992)
47. Aarsetoy H, Brugger-Andersen T, Hetland O., et al Long-term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb Haemost 2006;95:329-36.